Login / Signup

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC.

Fumio ImamuraTakako InoueKei KunimasaAki KubotaHanako KuharaMotohiro TamiyaKazumi NishinoMadoka KimuraKika KunoHayato KawachiToru Kumagai
Published in: Lung cancer management (2020)
Switch use of osimertinib seemed to produce improved efficacy for patients with activating EGFR mutations, because of the lack of patient selection via T790M.
Keyphrases
  • small cell lung cancer
  • epidermal growth factor receptor
  • advanced non small cell lung cancer
  • tyrosine kinase
  • brain metastases
  • case report
  • signaling pathway